CENTENNIAL, Colo.--(BUSINESS WIRE)--Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that the principal researcher for its ICA-1 compound, Dr. Mildred Acevedo-Duncan, will present the work for ICA-1 entitled “PKC-i inhibition by ICA-1 reduces the cell proliferation of Neuroblastoma” at the Ehrlich II, World Conference on Magic Bullets in Nurnberg, Germany on October 3-5, 2008.
